Innoviva Inc

XNAS:INVA

20.66

+0.04 (+0.19%)

7:30:08 PM EDT: $20.66 0.00 (0.00%)

Market Cap (Intraday)	1.50B
Current PE	4.19
Forward PE	8.36
2yr Forward PE	8.94

See more stats

Estimates Current Quarter

Revenue	$115.4 Million
Adjusted EPS	$0.53

See more estimates

10-Day MA	$21.01
50-Day MA	$21.31
200-Day MA	$21.77

See more pivots

Innoviva Inc Stock, XNAS:INVA

1350 Old Bayshore Highway, Suite 400, Burlingame, California 94010

United States of America

Phone: +1.650.238.9600

Number of Employees: 127

http://www.inva.com

Description

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.